Abstract
Objective: To assess the role of cerebellar global and sub-regional involvement on motor and cognitive impairment in multiple sclerosis (MS) patients. Background: The cerebellum plays a role in a wide variety of complex behaviors. Many evidences support a topographic division into “motor” and “non-motor” regions mapped to the anterior and posterior lobe of the cerebellum, respectively. Currently, no study has investigated the impact of structural cerebellar sub-regional involvement on motor and cognitive manifestations in MS patients. Methods: Cerebellar segmentation and lobular parcellation was performed on the 3D-T1-weighted brain images from 95 MS patients (53 relapsing remitting [RR] MS, 20 benign MS and 22 secondary progressive [SP] MS) and 32 healthy controls (HC) using the SUIT tool from SPM12. For all subjects, the Nine Hole Peg Test (9-HPT) was obtained as a measure of motor performance. MS patients also underwent cognitive evaluation, including the Paced Auditory Serial Addition Test (PASAT), Symbol Digit Modalities Test (SDMT) and Wisconsin Card Sorting Test (WCST). Spearman’s correlations between normalized cerebellar volumes vs motor and cognitive scores were estimated (p<0.05). Results: Global and regional cerebellar volumes did not differ between MS patients and HC. In MS patients, better 9-HPT performance correlated with higher global and regional cerebellar volumes, with stronger correlation with the anterior regions (lobules I-V) (p=0.02, r=0.24). In RRMS patients, better cognitive performance (SDMT, WCST) correlated with higher global and posterior-inferior (lobules VI-X) cerebellar volumes (p range: 0.008-0.01, r range: 0.30-0-32). Conclusions: Cerebellar posterior-inferior volume accounted for variance in cognitive measures in MS patients, whereas anterior cerebellar volume accounted for variance in motor performance, supporting a critical contribution of regional cerebellar damage to the clinical manifestations of MS. This study has been partially supported by a grant from FISM 2011/R/19 and Italian Ministry of Health (GR-2009-1529671).
Disclosure: Dr. D'Ambrosio has nothing to disclose. Dr. Rocca has nothing to disclose. Dr. Pagani has nothing to disclose. Dr. Riccitelli has nothing to disclose. Dr. Colombo has nothing to disclose. Dr. Rodegher has nothing to disclose. Dr. Falini has nothing to disclose. Dr. Comi has received personal compensation for activities with Teva, Novartis, Genzyme, Merck Serono, Biogen, Bayer, Actelion, Almirall, and Serono Symposia International Foundation. Dr. Filippi has received personal compensation for activities for consulting services and/or speaking activities from Biogen Idec, Excemed, Novartis, and Teva Pharmaceutical Industries.
Tuesday, April 19 2016, 8:30 am-7:00 pm
- Copyright © 2016 by AAN Enterprises, Inc.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.